Leronlimab for stroke recovery? "Preclinical sy
Post# of 151804
(Total Views: 606)
Posted On: 04/07/2025 11:57:24 PM
Leronlimab for stroke recovery?
"Preclinical systematic review of CCR5 antagonists as cerebroprotective and stroke recovery enhancing agents"
Link:
https://elifesciences.org/articles/103245
Highlights:
The overall body of preclinical evidence for CCR5 antagonists in stroke demonstrates potential acute cerebroprotection with corresponding impairment reduction, as well as improved functional recovery in the subacute/early chronic phase.
In conclusion, CCR5 antagonists show promise in preclinical studies for stroke cerebroprotection, corresponding reduction in impairment, as well as improved functional recovery related to neural repair in the late subacute/early chronic phase.
_________________________
On a related note, from the March 2025 Cytodyn Letter to Shareholders:
A new collaborator, Dr. Tom Carmichael, Professor and Chair of Neurology at the University of California, Los Angeles, has published important preclinical observations demonstrating how a small molecule CCR5 inhibitor can expedite recovery following a cerebrovascular accident (“CVA” or “stroke”). CytoDyn is working with Dr. Carmichael and Dr. Kate Schunke at the University of Hawaii to conduct a preclinical study of stroke in transgenic mice that express human CCR5. We are excited by this initiative, given our view that there is an unmet need for innovative and effective treatment paths for patients in this category, and our belief that the market for therapies to treat stroke and/or traumatic brain injury could grow significantly over the next several decades. Dr. Carmichael will also be advising on the pilot study of AD to be initiated at Cornell Medical Center in New York.
_________________________
I remain... #BULLISH
"Preclinical systematic review of CCR5 antagonists as cerebroprotective and stroke recovery enhancing agents"
Link:
https://elifesciences.org/articles/103245
Highlights:
The overall body of preclinical evidence for CCR5 antagonists in stroke demonstrates potential acute cerebroprotection with corresponding impairment reduction, as well as improved functional recovery in the subacute/early chronic phase.
In conclusion, CCR5 antagonists show promise in preclinical studies for stroke cerebroprotection, corresponding reduction in impairment, as well as improved functional recovery related to neural repair in the late subacute/early chronic phase.
_________________________
On a related note, from the March 2025 Cytodyn Letter to Shareholders:
A new collaborator, Dr. Tom Carmichael, Professor and Chair of Neurology at the University of California, Los Angeles, has published important preclinical observations demonstrating how a small molecule CCR5 inhibitor can expedite recovery following a cerebrovascular accident (“CVA” or “stroke”). CytoDyn is working with Dr. Carmichael and Dr. Kate Schunke at the University of Hawaii to conduct a preclinical study of stroke in transgenic mice that express human CCR5. We are excited by this initiative, given our view that there is an unmet need for innovative and effective treatment paths for patients in this category, and our belief that the market for therapies to treat stroke and/or traumatic brain injury could grow significantly over the next several decades. Dr. Carmichael will also be advising on the pilot study of AD to be initiated at Cornell Medical Center in New York.
_________________________
I remain... #BULLISH
(17)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼